Sign in
Not yet recruitingPhase 3

RASBU-SEPSIS Study: Effects of rasburicase on kidney during sepsis – a randomized, placebo-controlled, double-blind trial

Key facts

Who runs it
Assistance Publique Hopitaux De Paris
Where
France6 sites in 1 countryChoose a country to see its sites
Status
Not yet recruiting
Phase
Phase 3
People taking part
240 people, planned
Started
1 Dec 2025
Expected to end
1 Mar 2029
Type of study
Interventional
Record updated
15 September 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Patients ≥18 years old
  • Diagnosis of sepsis (presumed or known infection and increase in SOFA score ≥ 2), included within 48 hours of diagnosis
  • Uricémia ≥ 200 µmol/L
  • Rapid diagnostic test strip for G6PD deficiency negative
  • Patient affiliated with a social security scheme
  • Informed consent form signed
  • Woman of childbearing age using effective contraception throughout the treatment and for 1 month after the end of the treatment
  • Hospitalised in intensive care unit

Who cannot take part

  • Chronic treatment with a urate-lowering agent
  • Surgery involving the kidneys or urinary tract in the last 3 months
  • Other metabolic disorders known to cause hemolytic anemia
  • Chronic kidney failure on hemodialysis
  • Known hypersensitivity to Rasburicase, or to any of the excipients,
  • Pre-existing condition or situation at risk of lysis syndrome
  • Minor
  • Enrolled in another
  • Sepsis due to urinary obstruction
  • Life expectancy less than 6 months
  • Pregnant or breastfeeding woman
  • AKI with need for dialysis treatment estimated within 12 hours
  • Known G6PD deficiency or suggestive family history

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Determine the effect of Rasburicase on the occurrence and evolution of acute renal failure (ARF) in septic patients with uricemia ≥200 µmol/L.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
RASBU-SEPSIS Study: Effects of rasburicase on renal function during sepsis – a randomized, placebo-controlled, double-blind trial
Record updated
15 September 2026